Kreitman and co-workers [11] therefore conducted a phase II study investigating the BRAF inhibitor dabrafenib (150 mg b.i.d.)combined with the MEK inhibitor trametinib (2 mg once daily) for a median duration of 17 months in 43 relapsed and/or refractory HCL patients (Table 3). The gene discussed is MAP2K7; the disease is hairy cell leukemia.